South Korea's pharmaceutical firm GC Biopharma Corp. said on Monday that it has won a $44.3 million (57.9 billion won) order for flu vaccines in a drug tender offered by the Pan American Health Organization (PAHO), an arm of the World Health Organization (WHO).
Accordingly, GC's flu vaccine will be supplied to eight Latin American countries, including Honduras, Peru and Bolivia, in the first half of the year.
GC Biopharma's "GC flu quadrivalent" received WHO's prequalification (PQ) certification back in 2016. PQ is a certification for supplying vaccines to international relief organizations.
"With the expansion of quadrivalent flu vaccination overseas, we expect to see momentum in our sales growth and profitability going forward," said a company official.
We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.